Prader-Willi Syndrome



Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)


Condition:   Confirmed Genetic Diagnosis of Prader-Willi Syndrome
Interventions:   Drug: Tesofensine/Metoprolol;   Drug: Placebos
Sponsor:   Saniona
Recruiting - verified May 2017


Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory


Condition:   Prader-Willi Syndrome
Intervention:   Behavioral: Listening Project Protocol
Sponsors:   Indiana University;   Latham Centers
Not yet recruiting - verified March 2017


Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years


Condition:   Prader-Willi Syndrome
Interventions:   Drug: Oxytocin;   Drug: Placebo;   Drug: Oxytocin
Sponsor:   University Hospital, Toulouse
Recruiting - verified May 2017


Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.


Condition:   Prader-Willi Syndrome
Interventions:   Drug: Oxytocin;   Other: Control
Sponsor:   University Hospital, Toulouse
Recruiting - verified May 2017


Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome


Conditions:   Sleep Apnea, Central;   Prader-Willi Syndrome
Intervention:   Biological: Medical Air vs Oxygen
Sponsor:   The Hospital for Sick Children
Recruiting - verified January 2017


A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)


Condition:   Prader-Willi Syndrome
Intervention:   Drug: Diazoxide choline controlled-release tablet
Sponsor:   Essentialis, Inc.
Not yet recruiting - verified September 2016


Cannabidiol Oral Solution for The Treatment of Subjects With Prader-Willi Syndrome


Condition:   Prader-Willi Syndrome
Interventions:   Drug: Cannabidiol;   Drug: Placebo
Sponsor:   INSYS Therapeutics Inc
Not yet recruiting - verified April 2017


Register of Patients With Prader-Willi Syndrome


Condition:   Prader-Willi Syndrome
Intervention:   Other: Data collection
Sponsor:   University Hospital, Toulouse
Recruiting - verified July 2016


Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks


Condition:   Prader-Willi Syndrome
Interventions:   Drug: Topiramate;   Drug: Placebo Comparator
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified April 2016


Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome


Conditions:   Prader-Willi Syndrome;   Hyperphagia
Interventions:   Drug: Intranasal Oxytocin (IN-OXT);   Drug: Matched Placebo
Sponsors:   Montefiore Medical Center;   Foundation for Prader-Willi Research
Active, not recruiting - verified March 2017


Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome


Condition:   Obesity
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2017


Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome


Condition:   Prader-Willi Syndrome
Interventions:   Drug: Oxytocin continuous;   Drug: Placebo;   Drug: Placebo continuous;   Drug: Oxytocin
Sponsor:   University Hospital, Toulouse
Recruiting - verified June 2016


Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome


Condition:   Prader-Willi Syndrome
Interventions:   Drug: RM-493;   Drug: Placebo
Sponsor:   Rhythm Pharmaceuticals, Inc.
Completed - verified April 2017


Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants


Condition:   Prader Willi Syndrome
Intervention:   Drug: oxytocin
Sponsor:   University Hospital, Toulouse
Completed - verified May 2017


Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome


Conditions:   Prader-Willi Syndrome;   Obesity
Interventions:   Drug: ZGN-440 for Injectable Suspension;   Drug: ZGN-440 Placebo for Injectable Suspension
Sponsor:   Zafgen, Inc.
Terminated - verified January 2017


Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome


Condition:   Prader-Willi Syndrome
Interventions:   Drug: DCCR;   Drug: Placebo
Sponsor:   Essentialis, Inc.
Completed - verified August 2016


Prader-Willi Syndrome Macronutrient Study


Conditions:   Prader Willi Syndrome;   Syndromic Obesity;   Childhood Obesity
Interventions:   Other: Low Carbohydrate diet;   Other: Low Fat diet
Sponsors:   Duke University;   Foundation for Prader-Willi Research
Completed - verified December 2016


Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome


Conditions:   Hyperphagia;   Prader-Willi Syndrome
Intervention:   Device: tDCS
Sponsors:   University of Kansas Medical Center;   Prader-Willi Syndrome Association USA;   Harvard Medical School;   Foundation for Prader-Willi Research
Recruiting - verified September 2016


An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome


Conditions:   Obesity;   Over-weight;   Prader-Willi Syndrome
Interventions:   Drug: ZGN-440 sterile diluent;   Drug: 1.2 mg ZGN-440 for injectable suspension;   Drug: 1.8 mg ZGN-440 for injectable suspension
Sponsor:   Zafgen, Inc.
Completed - verified July 2016


Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome


Conditions:   Silver Russell Syndrome;   Prader-Willi Syndrome
Interventions:   Drug: Anastrozole;   Drug: Placebo
Sponsor:   Assistance Publique - Hôpitaux de Paris
Active, not recruiting - verified August 2016


Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies


Condition:   Prader-Willi Syndrome
Intervention:   Drug: Oxytocin
Sponsor:   University Hospital, Toulouse
Completed - verified February 2017


Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome


Condition:   Prader-Willi Syndrome
Intervention:   Drug: Exenatide
Sponsor:   Children's Hospital Los Angeles
Completed - verified September 2016


Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers


Conditions:   Genetic Disorder;   Prader-Willi Syndrome;   Growth Disorder;   Idiopathic Short Stature;   Healthy
Interventions:   Drug: somatropin;   Drug: somatropin
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017


Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo


Condition:   Prader Willi Syndrome
Interventions:   Drug: Syntocinon®/- Spray;   Drug: Physiological serum (Sodium chloride)
Sponsor:   University Hospital, Toulouse
Completed - verified May 2017


Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome


Condition:   Prader-Willi Syndrome
Intervention:   Drug: Norditropin SimpleXx
Sponsors:   Karolinska University Hospital;   Novo Nordisk A/S
Completed - verified September 2016

Refine Your Search Advanced Search